311 related articles for article (PubMed ID: 30442649)
41. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
42. Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters.
Ho YL; Gorycki P; Ferron-Brady G; Martin P; Vlasakakis G
Clin Transl Sci; 2024 Apr; 17(4):e13799. PubMed ID: 38634429
[TBL] [Abstract][Full Text] [Related]
43. Interaction of Sulfonylureas with Liver Uptake Transporters OATP1B1 and OATP1B3.
Chen Y; Chen L; Zhang H; Huang S; Xiong Y; Xia C
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):147-154. PubMed ID: 29498478
[TBL] [Abstract][Full Text] [Related]
44. Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8.
Tod M; Bourguignon L; Bleyzac N; Goutelle S
Clin Pharmacokinet; 2020 Jun; 59(6):757-770. PubMed ID: 31840223
[TBL] [Abstract][Full Text] [Related]
45. Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan.
Juif PE; Voors-Pette C; Ufer M; Dogterom P; Dingemanse J
Clin Transl Sci; 2019 Sep; 12(5):440-444. PubMed ID: 31004470
[TBL] [Abstract][Full Text] [Related]
46. Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers.
Takehara I; Terashima H; Nakayama T; Yoshikado T; Yoshida M; Furihata K; Watanabe N; Maeda K; Ando O; Sugiyama Y; Kusuhara H
Pharm Res; 2017 Aug; 34(8):1601-1614. PubMed ID: 28550384
[TBL] [Abstract][Full Text] [Related]
47. Static Model-Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics.
Taguchi T; Masuo Y; Futatsugi A; Kato Y
Drug Metab Dispos; 2020 Sep; 48(9):750-758. PubMed ID: 32616544
[TBL] [Abstract][Full Text] [Related]
48. The Drug-Drug Interaction Profile of Presatovir.
Xin Y; Weng W; Murray BP; Eisenberg EJ; Chien JW; Ling J; Silverman JA
J Clin Pharmacol; 2018 Jun; 58(6):771-780. PubMed ID: 29412463
[TBL] [Abstract][Full Text] [Related]
49. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
50. PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
Bolleddula J; Ke A; Yang H; Prakash C
CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):577-588. PubMed ID: 33822485
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of Organic Anion Transporting Polypeptide 1B1 and 1B3 by Betulinic Acid: Effects of Preincubation and Albumin in the Media.
Oh Y; Jeong YS; Kim MS; Min JS; Ryoo G; Park JE; Jun Y; Song YK; Chun SE; Han S; Bae SK; Chung SJ; Lee W
J Pharm Sci; 2018 Jun; 107(6):1713-1723. PubMed ID: 29462635
[TBL] [Abstract][Full Text] [Related]
52. Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
Samant TS; Huth F; Umehara K; Schiller H; Dhuria SV; Elmeliegy M; Miller M; Chakraborty A; Heimbach T; He H; Ji Y
Clin Pharmacol Ther; 2020 Sep; 108(3):575-585. PubMed ID: 32557601
[TBL] [Abstract][Full Text] [Related]
53. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
Treiber A; Schneiter R; Häusler S; Stieger B
Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
[TBL] [Abstract][Full Text] [Related]
54. Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
Robbins JA; Menzel K; Lassman M; Zhao T; Fancourt C; Chu X; Mostoller K; Witter R; Marceau West R; Stoch SA; McCrea JB; Iwamoto M
Clin Pharmacol Ther; 2022 Mar; 111(3):664-675. PubMed ID: 34888851
[TBL] [Abstract][Full Text] [Related]
55. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
56. Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes.
Takahashi T; Uno Y; Yamazaki H; Kume T
Biopharm Drug Dispos; 2019 Feb; 40(2):62-69. PubMed ID: 30652318
[TBL] [Abstract][Full Text] [Related]
57. Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.
Stader F; Kinvig H; Battegay M; Khoo S; Owen A; Siccardi M; Marzolini C
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686151
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice.
Bechtold BJ; Lynch KD; Oyanna VO; Call MR; White LA; Graf TN; Oberlies NH; Clarke JD
Drug Metab Dispos; 2024 Apr; 52(5):355-367. PubMed ID: 38485280
[TBL] [Abstract][Full Text] [Related]
59. Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects.
Liu L; Cheeti S; Yoshida K; Choo E; Chen E; Chen B; Gates M; Singel S; Morley R; Ware J; Sahasranaman S
J Clin Pharmacol; 2018 Nov; 58(11):1427-1435. PubMed ID: 29786857
[TBL] [Abstract][Full Text] [Related]
60. Luminogenic D-Luciferin Derivatives as OATP1B1 and 1B3 Substrates in No-wash Assays.
Ma D; Wang H; Ugo T; Mustafa D; Zhou W; Cali JJ
Photochem Photobiol; 2021 Nov; 97(6):1407-1416. PubMed ID: 33948961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
